| 来源类型 | Working Paper |
| 规范类型 | 报告 |
| DOI | 10.3386/w20212 |
| 来源ID | Working Paper 20212 |
| Pharmaceutical Profits and the Social Value of Innovation | |
| David Dranove; Craig Garthwaite; Manuel Hermosilla | |
| 发表日期 | 2014-06-12 |
| 出版年 | 2014 |
| 语种 | 英语 |
| 摘要 | Prior research has shown that exogenous shocks to the demand for medical products spur additional product development. These studies do not distinguish between breakthrough products and those that largely duplicate the performance of existing products. In this paper, we use a novel data set to explore the impact of the introduction of Medicare Part D on the development of new biotechnology products. We find that the law spurred development of products targeting illnesses that affect the elderly, but most of this effect is concentrated among products aimed at diseases that already have multiple existing treatments. Moreover, we find no increase in products targeting orphan disease or those receiving either fast track or priority review status from the FDA. This suggests that marginal changes in demand may have little effect on the development of products with large welfare benefits. |
| 主题 | Public Economics ; Health, Education, and Welfare ; Health |
| URL | https://www.nber.org/papers/w20212 |
| 来源智库 | National Bureau of Economic Research (United States) |
| 引用统计 | |
| 资源类型 | 智库出版物 |
| 条目标识符 | http://119.78.100.153/handle/2XGU8XDN/577886 |
| 推荐引用方式 GB/T 7714 | David Dranove,Craig Garthwaite,Manuel Hermosilla. Pharmaceutical Profits and the Social Value of Innovation. 2014. |
| 条目包含的文件 | 条目无相关文件。 | |||||
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
